Phase II Multicenter, Open-label, Clinical and Pharmacokinetic Study of Zalypsis (PM00104) in Patients With Unresectable Locally Advanced and/or Metastatic Ewing Family of Tumors (EFT) Progressing After at Least One Prior Line of Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2017
At a glance
- Drugs PM 00104 (Primary)
- Indications Ewing's sarcoma
- Focus Pharmacogenomic; Therapeutic Use
- 04 Jun 2012 Actual patients number is 17 as reported by ClinicalTrials.gov.
- 04 Jun 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
- 04 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.